A Phase 4 interventional study of Insulin glargine, 300U/mL and Insulin degludec, 100 U/mL in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 158 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 103 in phase 4, and was the 131st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 929 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 15th largest by enrollment of the 178 interventional ones that give a count, is one of 13 that started in 2016, is one of 75 in phase 4, and was the 136th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
Secondary Objectives:
Change From Baseline in HbA1c to Week 12
To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on:
To assess the safety in each treatment group.
To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO).
Percentage of participants requiring rescue therapy.
The maximum study duration per participant was approximately 27 weeks: an up to 2-week screening period, a 24-week randomized treatment period (including 12 weeks active titration), and a 7-day posttreatment safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
Drug: Insulin glargine, 300U/mL · Drug: Non-insulin anti-diabetic treatment
Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
Drug: Insulin degludec, 100 U/mL · Drug: Non-insulin anti-diabetic treatment
Drug page: Insulin Glargine
Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
Also known as: HOE901-U300, Toujeo
Drug page: Insulin degludec
Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L). Route of administration: subcutaneous
Also known as: Tresiba
Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
Change From Baseline in HbA1c to Week 24
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Adjusted Least Square (LS) means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the 24-week on-treatment period.
Time frame: Baseline, Week 24
Change From Baseline in HbA1c to Week 12
Change in HbA1c was calculated by subtracting baseline value from Week 12 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.
Time frame: Baseline, Week 12
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24
Change in FPG was calculated by subtracting baseline value from Week 12 and Week 24 value. Adjusted LS means were obtained from MMRM including post baseline values during the 24-week on-treatment period.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24
Fasting SMPG was measured by the participant before breakfast and before the administration of the glucose-lowering agents once a day during the study. Adjusted LS means were obtained from MMRM including post baseline values during the 24 week on treatment period.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point
8-point SMPG profiles were measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point
4-point SMPG profiles were measured at the following 4 points: prebreakfast, prelunch, predinner and bedtime.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24
The 8-point SMPG profile was measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Adjusted LS means were obtained from MMRM.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24
Adjusted LS means were obtained from MMRM. Variability was assessed by the mean of coefficient of variation calculated over at least 3 SMPG measured during the 7 days preceding the given visit.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24
Adjusted LS means were obtained from MMRM.
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24
Only the post-baseline HbA1c measurements before rescue and during the 12 week and 24-week on-treatment period were considered in the analysis.
Time frame: Week 12, and Week 24
Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed by plasma glucose =\<3.9 mmol/L (=\<70 mg/dL).
Time frame: Week 12, and Week 24
Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period
Percentage of participants With Sulphonylurea or Meglitinide dose reduction/ discontinuation due to Hypoglycemia during 24 Week treatment period were reported. Only participants with Sulphonylurea or meglitinides at Screening as per actual strata were taken into account in this analysis.
Time frame: Baseline to Week 24
Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. Threshold values at Week 12: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.
Time frame: Baseline to Week 24
Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24
Only the insulin dose measurements performed before initiation of rescue therapy and during the on-treatment period were considered in the analysis.
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks (24W)). Percentage of participants with at least one hypoglycemia (hypo) event at any time of the day were reported.
Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycaemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks).
Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L).
Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time).
Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24
The DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items that are answered on a Likert scale from 0 to 6. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment). Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.
Time frame: Baseline, Week 12 and Week 24
The study was conducted at 158 study centers across 16 countries. A total of 1376 participants were screened between 19 May 2016 and 19 February 2017, of whom 447 were screen failures.
| Milestone | Toujeo | Tresiba |
|---|---|---|
| Started | 466 | 463 |
| Treated | 462 | 462 |
| Completed | 443 | 432 |
| Not completed | 23 | 31 |
| Withdrew: Randomized but not treated | 4 | 1 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Hypoglycemia | 0 | 1 |
| Withdrew: Poor compliance to protocol | 4 | 3 |
| Withdrew: Other than specified above | 11 | 21 |
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Adjusted Least Square (LS) means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the 24-week on-treatment period.
| percentage of HbA1c | Toujeo | Tresiba |
|---|---|---|
| Change From Baseline in HbA1c to Week 24 | -1.64 ± 0.037 | -1.59 ± 0.037 |
Change in HbA1c was calculated by subtracting baseline value from Week 12 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.
| percentage of HbA1c | Toujeo | Tresiba |
|---|---|---|
| Change From Baseline in HbA1c to Week 12 | -1.37 ± 0.036 | -1.39 ± 0.036 |
Change in FPG was calculated by subtracting baseline value from Week 12 and Week 24 value. Adjusted LS means were obtained from MMRM including post baseline values during the 24-week on-treatment period.
| mmol/L | Toujeo | Tresiba |
|---|---|---|
| Week 12 | -3.64 ± 0.099 | -3.89 ± 0.100 |
| Week 24 | -3.52 ± 0.109 | -3.95 ± 0.110 |
Fasting SMPG was measured by the participant before breakfast and before the administration of the glucose-lowering agents once a day during the study. Adjusted LS means were obtained from MMRM including post baseline values during the 24 week on treatment period.
| mmol/L | Toujeo | Tresiba |
|---|---|---|
| Week 12 | -3.26 ± 0.067 | -3.25 ± 0.067 |
| Week 24 | -3.23 ± 0.067 | -3.29 ± 0.068 |
8-point SMPG profiles were measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
| mmol/L | Toujeo | Tresiba |
|---|---|---|
| Week 12: 03:00 at night | -2.77 ± 3.16 | -2.28 ± 3.49 |
| Week 12: Pre-breakfast | -3.42 ± 2.79 | -3.00 ± 2.63 |
| Week 12: 2 hours after breakfast | -3.20 ± 4.02 | -3.23 ± 3.92 |
| Week 12: Pre-lunch | -2.64 ± 3.90 | -2.50 ± 3.65 |
| Week 12: 2 hours after lunch | -2.51 ± 4.15 | -1.99 ± 3.94 |
| Week 12: Pre-dinner | -2.04 ± 3.63 | -1.93 ± 3.74 |
| Week 12: 2 hours after dinner | -2.32 ± 4.20 | -1.76 ± 3.87 |
| Week 12: Bedtime | -2.44 ± 4.07 | -2.08 ± 3.95 |
| Week 24: 03:00 at night | -2.65 ± 3.43 | -2.43 ± 3.51 |
| Week 24: Pre-breakfast | -3.37 ± 2.81 | -3.03 ± 2.85 |
| Week 24: 2 hours after breakfast | -3.30 ± 3.68 | -3.50 ± 4.00 |
| Week 24: Pre-lunch | -2.81 ± 3.67 | -2.29 ± 3.93 |
| Week 24: 2 hours after lunch | -2.74 ± 3.73 | -1.93 ± 3.91 |
| Week 24: Pre-dinner | -1.87 ± 3.78 | -1.86 ± 4.01 |
| Week 24: 2 hours after dinner | -2.28 ± 4.19 | -2.07 ± 4.00 |
| Week 24: Bedtime | -2.52 ± 3.87 | -2.09 ± 3.96 |
4-point SMPG profiles were measured at the following 4 points: prebreakfast, prelunch, predinner and bedtime.
| mmol/L | Toujeo | Tresiba |
|---|---|---|
| Week 12: Pre-breakfast | -3.41 ± 2.75 | -2.97 ± 2.62 |
| Week 12: Pre-lunch | -2.63 ± 3.88 | -2.44 ± 3.65 |
| Week 12: Pre-dinner | -2.03 ± 3.64 | -1.92 ± 3.76 |
| Week 12: Bedtime | -2.41 ± 4.10 | -2.11 ± 3.96 |
| Week 24: Pre-breakfast | -3.38 ± 2.81 | -2.99 ± 2.81 |
| Week 24: Pre-lunch | -2.81 ± 3.67 | -2.26 ± 3.92 |
| Week 24: Pre-dinner | -1.88 ± 3.79 | -1.86 ± 4.01 |
| Week 24: Bedtime | -2.51 ± 3.87 | -2.10 ± 4.00 |
The 8-point SMPG profile was measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Adjusted LS means were obtained from MMRM.
| mmol/L | Toujeo | Tresiba |
|---|---|---|
| Week 12 | -2.57 ± 0.092 | -2.50 ± 0.093 |
| Week 24 | -2.62 ± 0.094 | -2.53 ± 0.096 |
Adjusted LS means were obtained from MMRM. Variability was assessed by the mean of coefficient of variation calculated over at least 3 SMPG measured during the 7 days preceding the given visit.
| percentage of mean variability | Toujeo | Tresiba |
|---|---|---|
| Week 12 | 2.38 ± 0.418 | 2.62 ± 0.416 |
| Week 24 | 1.49 ± 0.391 | 1.97 ± 0.390 |
Adjusted LS means were obtained from MMRM.
| percentage of mean variability | Toujeo | Tresiba |
|---|---|---|
| Week 12 | 4.08 ± 0.562 | 4.73 ± 0.561 |
| Week 24 | 3.70 ± 0.588 | 3.95 ± 0.599 |
Only the post-baseline HbA1c measurements before rescue and during the 12 week and 24-week on-treatment period were considered in the analysis.
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Participants who reached the target <7% at Week 12 | 34.63 | 36.15 |
| Participants who reached target <=6.5% at Week 12 | 11.47 | 14.29 |
| Participants who reached the target <7% at Week 24 | 48.70 | 44.59 |
| Participants who reached target <=6.5% at Week 24 | 21.21 | 19.70 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed by plasma glucose =\<3.9 mmol/L (=\<70 mg/dL).
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Week12: Participants who reached the target <7% | 16.45 | 13.64 |
| Week12: Participants who reached target <=6.5% | 4.11 | 4.55 |
| Week24: Participants who reached the target <7% | 13.42 | 12.99 |
| Week24: Participants who reached target <=6.5% | 5.84 | 5.19 |
Percentage of participants With Sulphonylurea or Meglitinide dose reduction/ discontinuation due to Hypoglycemia during 24 Week treatment period were reported. Only participants with Sulphonylurea or meglitinides at Screening as per actual strata were taken into account in this analysis.
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period | 4.98 | 4.76 |
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. Threshold values at Week 12: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period | 1.30 | 1.30 |
Only the insulin dose measurements performed before initiation of rescue therapy and during the on-treatment period were considered in the analysis.
| Units per kilogram (U/kg) | Toujeo | Tresiba |
|---|---|---|
| Week 12 | 0.289 ± 0.200 | 0.255 ± 0.195 |
| Week 24 | 0.357 ± 0.253 | 0.309 ± 0.241 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks (24W)). Percentage of participants with at least one hypoglycemia (hypo) event at any time of the day were reported.
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Any hypo Day1-Week 12 | 53.0 | 58.4 |
| Any hypo Week13-14 | 57.2 | 57.4 |
| Any hypo 24 week period | 70.1 | 71.2 |
| Severe and/or confirmed hypo (=<70mg/dL) D1-W12 | 47.4 | 54.3 |
| Severe and/or confirmed hypo (=<70mg/dL) W13-14 | 54.1 | 55.8 |
| Severe and/or confirmed hypo(=<70mg/dL) 24W period | 66.5 | 69.0 |
| Severe and/or confirmed hypo (< 54mg/dL) D1-W12 | 7.8 | 11.7 |
| Severe and/or confirmed hypo( <54 mg/dL) W13-14 | 9.8 | 11.2 |
| Severe and/or confirmed hypo (<54mg/dL) 24W period | 14.7 | 18.4 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycaemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks).
| percentage of participants | Toujeo | Tresiba |
|---|---|---|
| Any hypo D1-W12 | 18.4 | 21.0 |
| Any hypo W13-14 | 22.7 | 21.2 |
| Any hypo 24Week period | 31.2 | 30.3 |
| Severe and/or confirmed hypo (=<70mg/dL)D1-W12 | 15.2 | 18.8 |
| Severe and/or confirmed hypo (=<70mg/dL)W13-14 | 21.4 | 21.0 |
| Severe and/or confirmed hypo(=<70mg/dL)24W Period | 28.6 | 28.8 |
| Severe and/or confirmed hypo(< 54mg/dL)D1-W12 | 2.8 | 3.5 |
| Severe and/or confirmed hypo(< 54mg/dL)W13-14 | 4.5 | 3.8 |
| Severe and/or confirmed hypo(< 54mg/dL)24W Period | 6.1 | 6.1 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L).
| Events per participant year | Toujeo | Tresiba |
|---|---|---|
| Any hypo Day1-Week12 | 8.93 | 11.31 |
| Any hypo Week13-14 | 11.28 | 11.60 |
| Any hypo 24 Week period | 10.09 | 11.45 |
| Severe and/or confirmed hypo (=<70mg/dL) D1-W12 | 8.08 | 10.47 |
| Severe and/or confirmed hypo (=<70mg/dL) W13-14 | 10.64 | 11.21 |
| Severe and/or confirmed hypo (≤70mg/dL) 24W period | 9.34 | 10.83 |
| Severe and/or confirmed hypo (< 54mg/dL) D1-W12 | 0.49 | 0.86 |
| Severe and/or confirmed hypo( <54 mg/dL) W13-14 | 0.73 | 0.91 |
| Severe and/or confirmed hypo (<54mg/dL) 24W period | 0.61 | 0.88 |
The DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items that are answered on a Likert scale from 0 to 6. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment). Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.
| score on a scale | Toujeo | Tresiba |
|---|---|---|
| Week 12 | 5.08 ± 0.246 | 5.32 ± 0.245 |
| Week 24 | 5.77 ± 0.257 | 5.44 ± 0.256 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time).
| Events per participant year | Toujeo | Tresiba |
|---|---|---|
| Any hypo D1-W12 | 1.65 | 2.36 |
| Any hypo W13-14 | 2.32 | 2.39 |
| Any hypo 24Week period | 1.98 | 2.38 |
| Severe and/or confirmed hypo(=<70mg/dL)D1-W12 | 1.42 | 2.20 |
| Severe and/or confirmed hypo(=<70mg/dL)W13-14 | 2.24 | 2.33 |
| Severe and/or confirmed hypo(=<70mg/dL)24W Period | 1.83 | 2.26 |
| Severe and/or confirmed hypo(< 54mg/dL)D1-W12 | 0.16 | 0.19 |
| Severe and/or confirmed hypo(< 54mg/dL)W13-14 | 0.33 | 0.26 |
| Severe and/or confirmed hypo(< 54mg/dL)24W Period | 0.24 | 0.22 |
Collected over All Adverse Events were collected from signature of the informed consent form until 7 days after last treatment administration (maximum exposure: 24 Weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Toujeo | 1/462 (0.2%) | 21/462 (4.5%) | 56/462 (12.1%) |
| Tresiba | 0/462 (0%) | 20/462 (4.3%) | 58/462 (12.6%) |
| Event | Toujeo | Tresiba |
|---|---|---|
| Acute Myocardial InfarctionCardiac disorders | 0/462 | 3/462 |
| Ischaemic StrokeNervous system disorders | 0/462 | 3/462 |
| Non-Cardiac Chest PainGeneral disorders | 0/462 | 2/462 |
| CellulitisInfections and infestations | 1/462 | 2/462 |
| Atrial FlutterCardiac disorders | 0/462 | 1/462 |
| BradycardiaCardiac disorders | 1/462 | 0/462 |
| Cardiac ArrestCardiac disorders | 0/462 | 1/462 |
| Coronary Artery DiseaseCardiac disorders | 1/462 | 1/462 |
| Coronary Artery InsufficiencyCardiac disorders | 0/462 | 1/462 |
| Myocardial InfarctionCardiac disorders | 1/462 | 0/462 |
| Event | Toujeo | Tresiba |
|---|---|---|
| Viral Upper Respiratory Tract InfectionInfections and infestations | 38/462 | 40/462 |
| Upper Respiratory Tract InfectionInfections and infestations | 24/462 | 19/462 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 60.6 ± 9.6 | 60.5 ± 9.8 | 60.5 ± 9.7 |
| Sex: Female, Male(Participants) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Female | 219 | 211 | 430 |
| Male | 247 | 252 | 499 |
| Race and Ethnicity Not Collected(Participants) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Body Mass Index (BMI)(Kg/m^2) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 31.7 ± 4.3 | 31.3 ± 4.4 | 31.5 ± 4.4 |
| Duration of Type 2 Diabetes Mellitus(years) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 10.5 ± 6.1 | 10.7 ± 6.5 | 10.6 ± 6.3 |
| Baseline HbA1c(Percentage of HbA1c) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 8.71 ± 0.83 | 8.57 ± 0.80 | 8.64 ± 0.82 |
| Basal Insulin Daily Dose(Units per kilogram (U/kg)) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 0.19 ± 0.04 | 0.12 ± 0.03 | 0.15 ± 0.05 |
Showing the first 100 of 158 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine